SynthesisFrontiers in medicine2026
Sarcopenia, frailty syndrome and obstructive sleep apnea as elements of the aging phenotype in head and neck cancer and upper airway disorders: a scoping review.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia, frailty syndrome, and obstructive sleep apnea (OSA) are increasingly recognized as age-related conditions with overlapping biological pathways. Their coexistence may be relevant in head and neck cancer and upper airway disorders, but direct evidence integrating OSA with head and neck cancer (HNC) and geriatric vulnerability remains limited. Objective: This scoping review aimed to map the evidence on the relationships among sarcopenia, frailty, and OSA in the context of head and neck cancer and upper airway disorders, and to determine whether the available literature supports an integrated clinical model linking OSA-related vulnerability with HNC outcomes. Methods: The review was conducted in accordance with PRISMA ScR guidelines. A literature search was performed in PubMed, EBSCO, and Google Scholar for studies published between January 2015 and December 2025. Eligible studies included adult populations and addressed sarcopenia, frailty, OSA, or their clinically relevant relationships in head and neck cancer and upper airway disorders. Results: Twelve studies met the inclusion criteria. Evidence clustered into two main streams. First, OSA was associated with frailty and sarcopenia-related phenotypes through mechanisms including intermittent hypoxia, systemic inflammation, sleep fragmentation, and neuroendocrine dysregulation. Second, in HNC, sarcopenia and frailty were associated with worse clinical outcomes, greater treatment burden, postoperative complications, treatment toxicity, and mortality. Direct evidence linking OSA with HNC within the included studies was limited. Therefore, the available evidence does not yet establish a fully demonstrated three-way clinical relationship among sarcopenia, frailty, and OSA in HNC. Conclusion: The available evidence supports clinically relevant overlap between OSA, frailty, and sarcopenia-related phenotypes, and a parallel association of sarcopenia and frailty with adverse HNC outcomes. However, the proposed triad should be interpreted as a hypothesis-generating framework rather than an established clinical entity. Future prospective studies should integrate objective OSA assessment, frailty evaluation, and radiological muscle measurements in HNC populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.